Last reviewed · How we verify
Tranexamic Acid Dosage 1
Tranexamic acid inhibits fibrinolysis by blocking plasminogen activation, thereby reducing excessive bleeding.
Tranexamic acid inhibits fibrinolysis by blocking plasminogen activation, thereby reducing excessive bleeding. Used for Prevention and treatment of hemorrhage in surgical procedures, Management of excessive bleeding in trauma and medical conditions.
At a glance
| Generic name | Tranexamic Acid Dosage 1 |
|---|---|
| Also known as | Cyklokapron, Transamin |
| Sponsor | Chinese Academy of Medical Sciences, Fuwai Hospital |
| Drug class | Antifibrinolytic agent |
| Target | Plasminogen / Plasmin |
| Modality | Small molecule |
| Therapeutic area | Hematology / Hemostasis |
| Phase | FDA-approved |
Mechanism of action
Tranexamic acid is a competitive inhibitor of plasminogen and plasmin, which are key enzymes in the fibrinolytic cascade responsible for breaking down blood clots. By preventing the conversion of plasminogen to plasmin, it stabilizes fibrin clots and reduces fibrin degradation, leading to decreased bleeding. This mechanism makes it effective in controlling hemorrhage in various surgical and medical settings.
Approved indications
- Prevention and treatment of hemorrhage in surgical procedures
- Management of excessive bleeding in trauma and medical conditions
Common side effects
- Thromboembolic events (deep vein thrombosis, pulmonary embolism)
- Gastrointestinal disturbances (nausea, vomiting, diarrhea)
- Headache
- Visual disturbances
Key clinical trials
- Tranexamic Acid for The Treatment of Gastrointestinal Bleeding (NA)
- Clinical Randomisation of an Anti-fibrinolytic in Symptomatic Mild Head Injury in Older Adults (PHASE3)
- Tranexamic Acid Dose and Remifentanil Titration in Septorhinoplasty
- Extended Oral Tranexamic Acid After Anterior Cruciate Ligament Reconstruction (PHASE4)
- One Versus Two Doses of Tranexamic Acid in Surgically Treated Extracapsular Hip Fractures (NA)
- The Effects of Tranexamic Acid on Joint Inflammation and Cartilage Health in Anterior Cruciate Ligament Injured Patients (PHASE2)
- Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children (PHASE3)
- Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |